China's JW Therapeutics interim revenue rises 4.7% on Carteyva sales

JW (Cayman) Therapeutics

27/08/2026 11:08

Overview
China cell immunotherapy developer's interim revenue grew 4.7% yr/yr, driven by Carteyva sales
Gross profit margin improved to 51.8%, though gross profit fell due to fewer license grants
Adjusted loss narrowed, mainly due to higher product revenue and reduced R&D expenses

Outlook
Company expects strengthened supply chain resilience and cost reductions from manufacturing localization
JW Therapeutics continues to focus on cost reduction and operational efficiency to support growth
Company anticipates expanded market coverage and ongoing commercialization of Carteya

Result Drivers
CARTEYVA SALES - Interim revenue growth was mainly driven by increased sales of Carteyva
COST REDUCTION - Company executed cost reduction plans, enabling a stable gross profit margin and reduced selling expense ratio
LOWER R&D EXPENSES - Decrease in R&D expenses due to cost reimbursements from Regeneron

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 111.40 mln
 

Analyst Coverage
Wall Street's median 12-month price target for JW (Cayman) Therapeutics Co Ltd is HK$6.04, about 168.4% above its August 27 closing price of HK$2.25

Reuters Recommended Reads
Aug 25 - China's Innovent Biologics H1 revenue, profit rise on strong product sales
Aug 24 - China's RemeGen H1 revenue soars on drug sales, AbbVie deal
Aug 26 - China's Hansoh Pharma posts 36% rise in first-half profit helped by innovative drug sales

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)